Budget impact of introducing an omalizumab biosimilar in 23 European countries
<p>Omalizumab, a monoclonal antibody indicated for severe persistent allergic asthma, chronic spontaneous urticaria (CSU), and chronic rhinosinusitis with nasal polyps (CRSwNP), imposes a financial burden on European healthcare systems due to its high cost, with expenditures exceeding €787 mil...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , |
| Published: |
2025
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!